Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.
Also called NCT01447654
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 130 participants
- Sponsor
- Henning Bundgaard
- Registry
-
NCT01447654
-
- Other papers using this trial's data
- Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial
- Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Denmark
- Registry status
- Completed
Technical summary
Registry record NCT01447654. Randomized; quadruple masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2014-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy
- Acronym
- INHERIT
- Condition
- Hypertrophic Cardiomyopathy
- Intervention (Drug)
- Losartan
- Intervention (Drug)
- Placebo
- Lead sponsor
- Henning Bundgaard
Record details
- Record id
cardio:ct-nct01447654- Content hash
0d1fe39af3fc1ee66eec444da905d827faed8ffc69831f71a9152889563a0394